93 related articles for article (PubMed ID: 35613620)
1. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
[TBL] [Abstract][Full Text] [Related]
2. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara D; Tran TH; Dharmaiah S; Stephens RM; McCormick F; Simanshu DK; Holderfield M
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22122-22131. PubMed ID: 31611389
[No Abstract] [Full Text] [Related]
3. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.
Agazie YM; Hayman MJ
Mol Cell Biol; 2003 Nov; 23(21):7875-86. PubMed ID: 14560030
[TBL] [Abstract][Full Text] [Related]
4. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.
Sherman LS; Atit R; Rosenbaum T; Cox AD; Ratner N
J Biol Chem; 2000 Sep; 275(39):30740-5. PubMed ID: 10900196
[TBL] [Abstract][Full Text] [Related]
5. PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis.
Pan R; Dai J; Liang W; Wang H; Ye L; Ye S; Lin Z; Huang S; Xiong Y; Zhang L; Lu L; Wang O; Shen X; Liao W; Lu X
Cell Death Dis; 2023 Jun; 14(6):373. PubMed ID: 37355626
[TBL] [Abstract][Full Text] [Related]
6. High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J; Jacob S; Kurupi R; Dalton KM; Coon C; Greninger P; Egan RK; Stein GT; Murchie E; McClanaghan J; Adachi Y; Hirade K; Dozmorov M; Glod J; Boikos SA; Ebi H; Hao H; Caponigro G; Benes CH; Faber AC
Cell Rep; 2022 Jul; 40(4):111095. PubMed ID: 35905710
[TBL] [Abstract][Full Text] [Related]
7. SHP2-EGFR States in Dephosphorylation Can Inform Selective SHP2 Inhibitors, Dampening RasGAP Action.
Liu Y; Jang H; Nussinov R
J Phys Chem B; 2024 May; 128(21):5175-5187. PubMed ID: 38747619
[TBL] [Abstract][Full Text] [Related]
8. K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins.
Magits W; Steklov M; Jang H; Sewduth RN; Florentin A; Lechat B; Sheryazdanova A; Zhang M; Simicek M; Prag G; Nussinov R; Sablina A
EMBO J; 2024 Jun; ():. PubMed ID: 38858602
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed imaging for probing RAS-RAF interactions in living cells.
Ahmad M; Movileanu L
Biochim Biophys Acta Biomembr; 2023 Aug; 1865(6):184173. PubMed ID: 37211322
[TBL] [Abstract][Full Text] [Related]
10. Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Carrot-Zhang J; Yao X; Devarakonda S; Deshpande A; Damrauer JS; Silva TC; Wong CK; Choi HY; Felau I; Robertson AG; Castro MAA; Bao L; Rheinbay E; Liu EM; Trieu T; Haan D; Yau C; Hinoue T; Liu Y; Shapira O; Kumar K; Mungall KL; Zhang H; June-Koo Lee J; Berger A; Gao GF; Zhitomirsky B; Liang WW; Zhou M; Moorthi S; Berger AH; Collisson EA; Zody MC; Ding L; Cherniack AD; Getz G; Elemento O; Benz CC; Stuart J; Zenklusen JC; Beroukhim R; Chang JC; Campbell JD; Hayes DN; Yang L; Laird PW; Weinstein JN; Kwiatkowski DJ; Tsao MS; Travis WD; Khurana E; Berman BP; Hoadley KA; Robine N; ; Meyerson M; Govindan R; Imielinski M
Cell Rep; 2021 Feb; 34(8):108784. PubMed ID: 33626341
[No Abstract] [Full Text] [Related]
11. Targeting RAF dimers in RAS mutant tumors: From biology to clinic.
Yin H; Tang Q; Xia H; Bi F
Acta Pharm Sin B; 2024 May; 14(5):1895-1923. PubMed ID: 38799634
[TBL] [Abstract][Full Text] [Related]
12. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y; Tao L; Qiu J; Xu J; Yang X; Zhang Y; Tian X; Guan X; Cen X; Zhao Y
Signal Transduct Target Ther; 2024 May; 9(1):132. PubMed ID: 38763973
[TBL] [Abstract][Full Text] [Related]
13. BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ; Chen Z; Rosen N; Solit DB
Nat Rev Clin Oncol; 2024 Mar; 21(3):224-247. PubMed ID: 38278874
[TBL] [Abstract][Full Text] [Related]
14. Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis.
Ta L; Tsai BL; Deng W; Sha J; Varuzhanyan G; Tran W; Wohlschlegel JA; Carr-Ascher JR; Witte ON
iScience; 2023 Dec; 26(12):108480. PubMed ID: 38089570
[TBL] [Abstract][Full Text] [Related]
15. Platycodin D represses β-catenin to suppress metastasis of cetuximab-treated KRAS wild-type colorectal cancer cells.
Lv Y; Wang W; Liu Y; Yi B; Chu T; Feng Z; Liu J; Wan X; Wang Y
Clin Exp Metastasis; 2023 Aug; 40(4):339-356. PubMed ID: 37326719
[TBL] [Abstract][Full Text] [Related]
16. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.
Dorard C; Madry C; Buhard O; Toifl S; Didusch S; Ratovomanana T; Letourneur Q; Dolznig H; Garnett MJ; Duval A; Baccarini M
Oncogene; 2023 May; 42(20):1649-1660. PubMed ID: 37020037
[TBL] [Abstract][Full Text] [Related]
17. Rare molecular subtypes of lung cancer.
Harada G; Yang SR; Cocco E; Drilon A
Nat Rev Clin Oncol; 2023 Apr; 20(4):229-249. PubMed ID: 36806787
[TBL] [Abstract][Full Text] [Related]
18. Dynamic regulation of RAS and RAS signaling.
Kolch W; Berta D; Rosta E
Biochem J; 2023 Jan; 480(1):1-23. PubMed ID: 36607281
[TBL] [Abstract][Full Text] [Related]
19. ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.
Su W; Mukherjee R; Yaeger R; Son J; Xu J; Na N; Merna Timaul N; Hechtman J; Paroder V; Lin M; Mattar M; Qiu J; Chang Q; Zhao H; Zhang J; Little M; Adachi Y; Han SW; Taylor BS; Ebi H; Abdel-Wahab O; de Stanchina E; Rudin CM; Jänne PA; McCormick F; Yao Z; Rosen N
Mol Cell; 2022 Jul; 82(13):2443-2457.e7. PubMed ID: 35613620
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
